GeneOne Life Science

GeneOne Life Science (GLS) is a KOSPI-listed company headquartered in Seoul, South Korea. The company, whose entry into biotechnology began in 2005, "is focused on gene-based therapies and vaccines". The company changed names twice, from Dong-Il Fabric to VGXI International to its current label in 2014. Its "global clinical development group is based in Blue Bell, Pennsylvania. VGXI Inc. is a wholly owned subsidiary and is based in Woodlands, Texas. VGXI is known as the largest Contract Manufacturing Organization able to supply cGMP-grade DNA plasmids for clinical use.

History

Before August 2016, GLS began tests of a DNA vaccine against Zika in Miami, due to the outbreak there which had infected at least 14 people. The injection technique of electroporation is employed by GLS, in which "genes from the virus are shot under high pressure into a person’s arm."

In April 2020, GLS and Inovio shared positive results for their MERS DNA vaccine.

In May 2020, GLS announced FDA approval of a Phase 2 Study of their GLS-1200 nasal spray product for COVID-19 prevention. Their product seeks to train cells to produce nitric oxide which "has been shown to inhibit SARS coronavirus growth and infectivity... The study will investigate whether three-times daily nasal administration of GLS-1200 over 4 weeks can prevent infection with COVID-19 while in use."

References

This article "GeneOne Life Science" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:GeneOne Life Science. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.

📰 Article(s) of the same category(ies)

• Stemgent
• List of United States Congress members who contracted COVID-19
• Vaccine imperialism
• Connecticut Biotech
• Biotech and pharmaceutical companies in the New York metropolitan area
• Misinformation related to the COVID-19 pandemic by the United States
• Johanson3

---